Integrating quantum mechanics into drug discovery marks a decisive shift from empirical trial-and-error toward quantitative precision. However, the prohibitive cost of ab initio molecular dynamics has historically forced a compromise between chemical accuracy and computational scalability. This paper identifies the convergence of High-Performance Computing (HPC), Machine Learning (ML), and Quantum Computing (QC) as the definitive solution to this bottleneck. While ML foundation models, such as FeNNix-Bio1, enable quantum-accurate simulations, they remain tethered to the inherent limits of classical data generation. We detail how High-Performance Quantum Computing (HPQC), utilizing hybrid QPU-GPU architectures, will serve as the ultimate accelerator for quantum chemistry data. By leveraging Hilbert space mapping, these systems can achieve true chemical accuracy while bypassing the heuristics of classical approximations. We show how this tripartite convergence optimizes the drug discovery pipeline, spanning from initial system preparation to ML-driven, high-fidelity simulations. Finally, we position quantum-enhanced sampling as the beyond GPU frontier for modeling reactive cellular systems and pioneering next-generation materials.

翻译：将量子力学融入药物发现标志着从经验试错向定量精确性的决定性转变。然而，从头算分子动力学的巨大计算成本历来迫使人们在化学准确性与计算可扩展性之间做出妥协。本文指出，高性能计算（HPC）、机器学习（ML）与量子计算（QC）的融合是解决这一瓶颈的终极方案。尽管以FeNNix-Bio1为代表的机器学习基础模型能够实现量子精度的模拟，但其性能仍受限于经典数据生成的内在边界。我们详细阐述了如何利用混合QPU-GPU架构的高性能量子计算（HPQC），将其作为量子化学数据的终极加速器。通过利用希尔伯特空间映射，此类系统可在规避经典近似启发式局限的同时实现真正的化学精度。我们揭示了这一三方融合如何优化药物发现流程，涵盖从初始系统准备到机器学习驱动的高保真模拟全链条。最后，我们将量子增强采样定位为超越GPU极限的前沿技术，用于模拟反应性细胞系统并开创下一代材料研发。